Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Am Heart J ; 178: 168-75, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27502865

RESUMO

AIMS: In the IMMEDIATE Trial, intravenous glucose-insulin-potassium (GIK) was started as early as possible for patients with suspected acute coronary syndrome by ambulance paramedics in communities. In the IMMEDIATE Biological Mechanism Cohort substudy, reported here, we investigated potential modes of GIK action on specific circulating metabolic components. Specific attention was given to suppression of circulating oxygen-wasting free fatty acids (FFAs) that had been posed as part of the early GIK action related to averting cardiac arrest. METHODS: We analyzed the changes in plasma levels of FFA, glucose, C-peptide, and the homeostasis model assessment (HOMA) index. RESULTS: With GIK, there was rapid suppression of FFA levels with estimated levels for GIK and placebo groups after 2 hours of treatment of 480 and 781 µmol/L (P<.0001), even while patterns of FFA saturation remained unchanged. There were no significant changes in the HOMA index in the GIK or placebo groups (HOMA index: placebo 10.93, GIK 12.99; P = .07), suggesting that GIK infusions were not countered by insulin resistance. Also, neither placebo nor GIK altered endogenous insulin secretion as reflected by unchanging C-peptide levels. CONCLUSION: These mechanistic observations support the potential role of FFA suppression in very early cardioprotection by GIK. They also suggest that the IMMEDIATE Trial GIK formula is balanced with respect to its insulin and glucose composition, as it induced no endogenous insulin secretion.


Assuntos
Síndrome Coronariana Aguda/tratamento farmacológico , Serviços Médicos de Emergência/métodos , Glucose/uso terapêutico , Parada Cardíaca/prevenção & controle , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Potássio/uso terapêutico , Síndrome Coronariana Aguda/sangue , Idoso , Angina Pectoris/sangue , Angina Pectoris/tratamento farmacológico , Glicemia/metabolismo , Peptídeo C/sangue , Intervenção Médica Precoce , Eletrocardiografia , Ácidos Graxos não Esterificados/sangue , Feminino , Parada Cardíaca/sangue , Humanos , Infusões Intravenosas , Resistência à Insulina , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio sem Supradesnível do Segmento ST/sangue , Infarto do Miocárdio sem Supradesnível do Segmento ST/tratamento farmacológico , Infarto do Miocárdio com Supradesnível do Segmento ST/sangue , Infarto do Miocárdio com Supradesnível do Segmento ST/tratamento farmacológico
2.
Metabolism ; 56(7): 910-4, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17570251

RESUMO

The effect of body mass index (BMI) and obesity on apolipoprotein (apo) A-I levels and kinetics was examined by gender. Apo A-I kinetics were determined with a primed, constant infusion of deuterated leucine in the fed state in 19 men and 13 postmenopausal women. Compared with nonobese men, nonobese women had a higher level of high-density lipoprotein cholesterol (HDL-C) and apo A-I due to a 48% higher apo A-I production rate (PR) (P = .05). Obesity had no significant effects on apo A-I kinetics in women. In contrast, compared with nonobese men, obese men had a 9% lower apo A-I level due to a 64% higher fractional catabolic rate (FCR) partially offset by a 47% higher PR. Obese women had a 52% higher HDL-C than obese men (50 vs 33 mg/dL, respectively; P = .012), a finding related to the faster apo A-I FCR in obese men. BMI was directly correlated with apo A-I FCR (r = 0.84, P < .001) and PR (r = 0.79, P < .001) in men but not in women. Sixty-two percent of the variability in PR and 71% of the variability in FCR were due to BMI in men and only 3% and 23%, respectively, in women. In conclusion, BMI has a significant effect on apo A-I PR and FCR in men but not in women.


Assuntos
Apolipoproteína A-I/sangue , Índice de Massa Corporal , Obesidade/sangue , Adulto , Idoso , Apolipoproteína A-I/biossíntese , HDL-Colesterol/sangue , Feminino , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Pós-Menopausa/sangue
4.
Mass Spectrom Rev ; 24(3): 311-27, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15389849

RESUMO

Obesity is recognized as a major public health problem. Obesity is a multifactorial disease and is often associated with a wide range of comorbidities including hypertension, non-insulin dependent (Type II) diabetes mellitus, and cardiovascular disease, all of which contribute to morbidity and mortality. This review deals with stable isotope mass spectrometric methods and the application of stable isotopes to metabolic studies of obesity. Body composition and total energy expenditure (TEE) can be measured by mass spectrometry using stable isotope labeled water, and the metabolism of protein, lipid, and carbohydrate can be measured using appropriate labeled tracer molecules.


Assuntos
Isótopos , Espectrometria de Massas , Obesidade/diagnóstico , Obesidade/metabolismo , Metabolismo Energético , Humanos
5.
Metabolism ; 53(10): 1255-61, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15375779

RESUMO

The metabolism of apolipoproteins (apo)B-48, B-100, and A-I was studied with a primed constant infusion of deuterium-labeled leucine in the fed state in 3 male individuals with chronic kidney disease (CKD), a glomerular filtration rate (GFR) of 28 to 57 mL/min/1.73 m2, obesity (body mass index [BMI] 33.1), and the metabolic syndrome. Compared to 5 obese controls (BMI 30.1) and 13 non-obese controls (BMI 25.2), these CKD subjects had high plasma levels of triglycerides (TG) (343 +/- 27.5 mg/dL v 144 +/- 34.4 in the obese controls, P < .001) and low apoA-I (86.7 +/- 3.9 mg/dL). An abnormal high-density lipoprotein (HDL) particle subpopulation pattern was found, with low levels of pre beta-1 and alpha1. Compared to the obese controls, very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) apoB-100 levels were elevated 2- to 3-fold, while LDL apoB-100 levels were slightly lower (-7 %) and apoB-48 levels were comparable. The high TG levels were not associated with statistically significant changes in VLDL apoB-100 kinetics, although the production rate (PR) was higher and the fractional catabolic rate (FCR) was lower. The slightly lower LDL apoB-100 levels were accompanied by a significant 3-fold increase in the FCR and a 2.7-fold increase in the PR. The lower apoA-I levels were accompanied by a 1.6-fold increase in the FCR. Compared to the non-obese controls, the PR of apoA-I was increased by 61% and 38%, respectively (P < .001) in CKD and in obese control subjects. In the control subjects, the PR of apoA-I was significantly correlated with the BMI (r = 0.81, P < .0001). The kinetic results are consistent with these hypotheses: (1) CKD is associated with decreased clearance of the TG-rich lipoproteins (TRLs) and increased catabolism of LDL; (2) obesity increases apoB-100 and apoA-I production; and (3) in CKD, TG transfer to HDL, making HDL more susceptible to catabolism, accounts for the low apoA-I levels.


Assuntos
Apolipoproteína A-I/metabolismo , Apolipoproteínas B/metabolismo , Nefropatias/metabolismo , Síndrome Metabólica/metabolismo , Obesidade/metabolismo , Idoso , Apolipoproteína B-100 , Apolipoproteína B-48 , Colesterol/sangue , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Doença Crônica , Taxa de Filtração Glomerular/fisiologia , Humanos , Hiperlipidemias/etiologia , Nefropatias/complicações , Lipídeos/sangue , Lipoproteínas/sangue , Masculino , Síndrome Metabólica/complicações , Pessoa de Meia-Idade , Modelos Biológicos , Obesidade/complicações
6.
Nutr Rev ; 61(11): 363-75, 2003 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-14677571

RESUMO

The paradigm of obesity leading to insulin resistance and type 2 diabetes is examined in relation to dyslipidemia, which typically consists of high levels of triglycerides (TG) and low levels of high-density lipoprotein (HDL). Kinetic studies with stable isotope-labeled amino acid precursors have shown that the development of visceral obesity, as well as type 2 diabetes, leads to overproduction of the apolipoprotein B-100 and TG in very low-density lipoproteins. Elevated plasma levels or increased flux of albumin-bound free fatty acids to the liver appear to be underlying metabolic events in this process. Low levels of HDL are due to increased catabolism, which can be related to TG enrichment.


Assuntos
Diabetes Mellitus/metabolismo , Lipoproteínas/metabolismo , Obesidade , Apolipoproteína B-100 , Apolipoproteínas B/metabolismo , HDL-Colesterol/sangue , Humanos , Isótopos , Triglicerídeos/sangue , Redução de Peso/fisiologia
7.
J Lipid Res ; 43(12): 2155-63, 2002 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-12454278

RESUMO

Fatty acids of varying lengths and saturation differentially affect plasma apolipoprotein B-100 (apoB-100) levels. To identify mechanisms at the level of production, rat hepatoma cells, McA-RH7777, were incubated with [(35)S]methionine and either fatty acid-BSA complexes or BSA alone. There were increases in labeled apoB-100 secretion with saturated fatty acids palmitic and myristic (MA) (153 +/- 20% and 165 +/- 11%, respectively, relative to BSA). Incubation with polyunsaturated docosahexaenoic acid (DHA) decreased secretion to 26 +/- 2.0%, while monounsaturated oleic acid (OA) did not change it. In pulse-chase studies, MA treatment resulted in reduced apoB-100 degradation, in agreement with its promotion of secretion. In triglyceride (TG) studies, synthesis was stimulated equally by OA, MA, and DHA, but TG secretion was relatively decreased with MA and DHA. With OA, the majority of newly secreted apoB100-lipoproteins was d < or = 1.006, but with MA, they were much denser (1.063 < d). Furthermore, the relative recruitment of newly synthesized TG to lipoproteins was impaired with MA. We conclude that mechanisms for effects of specific dietary fatty acids on plasma lipoprotein levels may include changes in hepatic production. In turn, hepatic production may be regulated by specific fatty acids at the steps of apoB-100 degradation and the recruitment of nascent TG to lipoprotein particles.


Assuntos
Apolipoproteínas B/metabolismo , Lipoproteínas/metabolismo , Ácido Mirístico/metabolismo , Triglicerídeos/metabolismo , Animais , Carcinoma Hepatocelular , Técnicas In Vitro , Ratos , Células Tumorais Cultivadas
8.
Front Biosci ; 7: e326-38, 2002 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-12133820

RESUMO

This review covers lipids, apolipoproteins, and receptors involved in the dyslipidemia of the nephrotic syndrome in humans and in rat or mouse models of the syndrome. It emphasizes research published during the last decade, though earlier work is cited. The focus is on the biosynthesis and catabolism of the plasma lipoprotein density classes and the role of receptors and enzymes in regulating lipoprotein metabolism in nephrosis. Although the factors responsible for the initiation of the hepatic and peripheral cellular responses to proteinuria and hypoalbuminemia remain elusive, recent work highlights the increased risk of atherosclerosis and the progression of renal disease associated with nephrotic dyslipidemia. Understanding of the role of the kidney in the catabolism of apolipoproteins entering the glomerular filtrate has been enhanced by the discovery of the receptor-mediated uptake of apolipoprotein A-I, the main apoprotein of HDL. The following aspects of lipid and lipoprotein metabolism in relation to nephrosis are discussed, with attention paid to differences between experimental nephrosis and the human nephrotic syndrome:(1) Albumin metabolism (2) Lipoprotein metabolism (3) Receptors (4) LCAT and CETP (5) Hepatic and Lipoprotein Lipase (6) Lipid metabolism (7) Lipiduria (8) Hypotheses and Questions (9) Summary.


Assuntos
Lipoproteínas/metabolismo , Síndrome Nefrótica/metabolismo , Animais , Humanos , Lipoproteínas/sangue , Síndrome Nefrótica/sangue , Síndrome Nefrótica/enzimologia , Síndrome Nefrótica/fisiopatologia
9.
Atherosclerosis ; 162(2): 227-44, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11996942

RESUMO

This article reviews the literature from 1986 to early 2001 relating to apoB100 and apoB48 kinetics in humans using amino acid precursors labeled with stable isotopes. The following subjects are reviewed: (1) methodology; (2) normal individuals and the effects of aging; (3) diet; (4) hereditary dyslipidemias: familial hypercholesterolemia, familial combined hyperlipidemia, cholesteryl ester storage disease, cholesteryl ester transfer protein deficiency, lipoprotein lipase deficiency, familial hypobetalipoproteinemia, and truncated forms of apoB; (5) hormonal perturbations: estrogen, insulin, diabetes, obesity, and growth hormone; (6) the nephrotic syndrome; and (7) the effects of the statin class of drugs. Because of the advances which have been made in mass spectrometry techniques, the advantages of using non-radioactive tracers in humans have made stable isotope kinetic studies the present day standard in this area of research.


Assuntos
Apolipoproteínas B/metabolismo , Aminoácidos , Doenças Genéticas Inatas/metabolismo , Hormônios/fisiologia , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Isótopos , Síndrome Nefrótica/metabolismo , Precursores de Proteínas , Valores de Referência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA